Immune checkpoint inhibition: prospects for prevention and therapy of hepatocellular carcinoma.

ABSTRACT: The global prevalence of liver cancer is rapidly rising, mostly as a result of the amplified incidence rates of viral hepatitis, alcohol abuse and obesity in recent decades. Treatment options for liver cancer are remarkably limited with sorafenib being the gold standard for advanced, unresectable hepatocellular carcinoma but offering extremely limited improvement of survival time. The immune system is now recognised as a key regulator of cancer development through its ability to protect against infection and chronic inflammation, which promote cancer development, and eliminate tumour cells when present. However, the tolerogenic nature of the liver means that the immune response to infection, chronic inflammation and tumour cells within the hepatic environment is usually ineffective. Here w

SUBMITTER: Elsegood CL 

PROVIDER: S-EPMC5704099 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature